Screener
Capricor Therapeutics CAPR Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The source filing: Capricor Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 5:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-060382
| Line item | March 31, 2026 / (unaudited) | December 31, 2025 | December 31, 2025 |
|---|---|---|---|
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||
| CURRENT LIABILITIES | |||
| Accounts payable | $3,927,941 | $ | $1,654,754 |
| Accrued expenses | 10,528,351 | 15,557,646 | |
| Lease liabilities, current | 841,135 | 202,376 | |
| CIRM liability, current | 6,339,862 | 6,421,984 | |
| Deferred revenue, current | 12,000,000 | 12,000,000 | |
| TOTAL CURRENT LIABILITIES | 33,637,289 | 35,836,760 |
Item 1. Financial Statements.
FAQ
- What is Capricor Therapeutics's accrued expenses?
- Capricor Therapeutics (CAPR) reported accrued expenses of $10.53M in Q1 2026.
- How has Capricor Therapeutics's accrued expenses changed year-over-year?
- Capricor Therapeutics's accrued expenses increased by 148.2% year-over-year, from $4.24M to $10.53M.
- What is the long-term trend for Capricor Therapeutics's accrued expenses?
- Over 3 years (2022 to 2025), Capricor Therapeutics's accrued expenses has grown at a 458.6% compound annual growth rate (CAGR), from $89.23K to $15.56M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Capricor Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude